The gut microbiota drives individual sensitivity to excess acetaminophen (APAP)-mediated
hepatotoxicity. It has been reported that the bacterium Akkermansia muciniphila protects …

Accumulating evidence indicates that gut microbiota participates in the pathogenesis and
progression of liver diseases. The severity of immune-mediated liver injury is associated …

Akkermansia muciniphila, as a member of the gut microbiota, has been proposed as a next-
generation probiotic. Liver fibrosis is the main determinant of liver dysfunction and mortality …

The gut bacterium Akkermansia muciniphila has been increasingly recognized for its
therapeutic potential in treating metabolic disorders, including obesity, diabetes, and …

Inflammation plays a critical role in the promotion of hepatocyte damage and liver fibrosis. In
recent years the protective role of Akkermansia muciniphila, a next-generation beneficial …

Gut microbiota are closely related to lipopolysaccharide (LPS)-induced acute lung injury
(ALI). Akkermansia muciniphila (A. muciniphila) maintains the intestinal barrier function and …

It has been reported that Akkermansia muciniphila improves host metabolism and reduces
inflammation; however, its potential effects on bile acid metabolism and metabolic patterns …

Current evidence indicates that the next-generation probiotic Akkermansia muciniphila (A.
muciniphila) has therapeutic potential for nonalcoholic fatty liver disease (NAFLD) …

Gut microbiota plays a key role in obesity and non-alcoholic fatty liver disease (NAFLD), so
synbiotics could be a therapeutic alternative. We aim to evaluate a nutritional intervention …

Acetaminophen (APAP) overdose is the most common driver of drug-induced liver injury
(DILI) worldwide, and the gut microbiome plays a crucial role in this process. In this study …